Mind Medicine MindMed (MNMD)
(Delayed Data from NSDQ)
$7.32 USD
-0.16 (-2.14%)
Updated Jun 18, 2024 04:00 PM ET
After-Market: $7.32 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Mind Medicine (MindMed) Inc. [MNMD]
Reports for Purchase
Showing records 21 - 40 ( 73 total )
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Analyst Day Highlights, Late 2023 for Highly Informative MM-120 Data
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
MM-402 Delivers Encouraging Preclinical Results In Animal Model of ASD
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
New Expert Report Undercuts Activist Disdain for MM-120 Phase 2b Trial
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 GAD Trial More Than Half Enrolled, Making 4Q23 Data Highly Likely
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Management Meeting Highlights MM-120 in Anxiety and ADHD on Track With Phase 2 Data Expected 2H23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
1Q23: Clinical Data Catalysts and More Coming Over 2023, Funded Into 1H25
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Investigator Trial Points to Potential of LSD in Depression; Phase 2 Data in Anxiety on Track for 2H23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Collaborators at UHB Show Positive Phase 2 MDD Data With LSD
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
4Q22 Results; MM-120 on Track for Phase 2 Readouts on Anxiety and ADHD in 4Q23; MM-420 Progressing in Autism; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
4Q22: Clinical Readout Catalysts and More Coming in 2023, Funded Into 1H25
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Bullish Start to the Year for Psychedelic Drug Development Companies Ahead of a Plethora of Potential Positive Events
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
MM-120 on Track to Generate Phase 2 Data in Anxiety and ADHD Late in 2023; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Transfer of Coverage, Establishing Buy Rating and $25 Price Target
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J